The Life Sciences team advised Noetik in a five-year strategic collaboration and AI model licensing agreement with GSK.
The partnership provides GSK’s AI and Therapeutics teams with a direct, non-exclusive license to access Noetik’s OCTO-VC virtual cell foundation models in non-small cell lung cancer (NSCLC) and colorectal cancer (CRC). The companies will further collaborate to generate bespoke human spatial datasets, applying human-first biological simulation to areas of strategic interest.
This collaboration includes $50 million in upfront capital and near-term milestones to Noetik. Additionally, the deal establishes a subscription-based framework, with GSK paying annual licensing fees to access the models, validating Noetik’s platform as a scalable, revenue-generating engine.
Noetik is a frontier therapeutics company harnessing AI to deeply understand human biology and redefine clinical outcomes in oncology. Leveraging the largest proprietary multimodal oncology dataset of its kind, uniquely integrating spatial biology, Noetik’s OCTO series of models (Oncology Counterfactual Therapeutics Oracle) precisely match therapeutic targets to patient subpopulations and accurately predict clinical efficacy. This AI-first approach elevates therapeutic development from probabilistic guesswork to precision science. By strategically partnering with clinical developers and in-licensing promising therapeutics, Noetik accelerates the delivery of transformative cancer treatments to patients.
The Goodwin deal team was led by Beth Withers, Erini Svokos, and Martha Schreck, with invaluable assistance from Curtis McCluskey.